4 天前 - … Heart failure (HF) has emerged as the most pressing health concerns globally,
and … the potential of Nrf2 to exert unique cardioprotective functions as a novel therapeutic …

4 天前 - … They have become a crucial component of therapeutic guidelines for congestive
heart failure and proteinuric chronic kidney disease (CKD). These benefits extend beyond …

4 天前 - … heart failure. It is triggered by disrupted transforming growth factor (TGF)-β signaling,
including loss-of-function mutations in the bone morphogenetic protein (BMP) receptor 2. …

4 天前 - … 4 Whether and to which extent a given genetic background is related to the
underlying atrial substrate and a potential tailored interventional therapy is not yet understood. …

5 天前 - … The potential of the pericardial space as a therapeutic delivery tool for cardiac
fibrosis and heart failure (… around the translational and therapeutic potential of exosome-related …

5 天前 - … therapeutic benefits in specific subsets of 11 cardiomyopathies akin to their efficacy
in other heart failure … heart failure resulting from vascular 13 diseases and other causes of …

6 天前 - … progression and the development of end-stage heart failure. Recombinant
adeno-associated virus (AAV)-mediated gene therapy presents a promising avenue for targeted …

6 天前 - … A few ischemic and non-ischemic heart failure patients have produced donor-specific
antibodies against the MHC class I antigen, persisting for more than one month following …

6 天前 - … Heart failure with preserved ejection fraction (HFpEF) is a common subtype of
heart failure marked by impaired left ventricular diastolic function and decreased myocardial …

6 天前 - … This proposition gained further support from trials 91 dedicated to heart failure (HF)
and chronic kidney disease (CKD) treatment, conducted in 92 patients with and without T2D …